Previous Article | Next Article ![]()
Journal of Clinical Microbiology, August 2007, p. 2575-2579, Vol. 45, No. 8
0095-1137/07/$08.00+0 doi:10.1128/JCM.00062-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Biotechnology and Food Engineering, Technion, Haifa, Israel,1 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel,2 The Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel3
Received 9 January 2007/ Returned for modification 3 June 2007/ Accepted 14 June 2007
Salmonella enterica serovar Virchow is highly prevalent in humans and farm animals in Israel. In addition to high rates of resistance to multiple antibiotics, this serovar exhibits a high incidence of resistance to nalidixic acid. More than 90% of Salmonella serovar Virchow isolates of human and poultry origin obtained from 1997 to 2004 were resistant to nalidixic acid (MIC
128 µg/ml), with reduced susceptibility to ciprofloxacin (MIC between 0.125 and 0.250 µg/ml). Most isolates belonged to two predominant, closely related pulsed-field gel electrophoresis image types. Investigation of the mechanisms of quinolone resistance revealed that this pathogen probably emerged from a parental clone that overproduced the AcrAB efflux pump and had a single point mutation in gyrA leading to the Asp87Tyr substitution. The close resemblance between human and poultry isolates points to poultry as a likely source of Salmonella serovar Virchow in the food chain.
Published ahead of print on 27 June 2007.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»